Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Connect Biopharma Holdings Ltd

CNTB ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.55

▲ +0.39%

Market Cap $160.58M · Vol 54.59K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$160.58M

Micro Cap

Div Yield

N/A

EPS Growth

-5.88%

YoY

RSI (14)

75.00

Momentum

Beta

-0.24

vs Market

52W High

$3.74

31.73% below

52W Low

$1.24

105.65% above

Volume

54.59K

Avg 156.80K

P/B

3.79

Price-to-book

ROE

N/A

Return on equity

Free Float

66.91%

Public shares

Shariah Compliance8 STANDARDS

✗ Connect Biopharma Holdings Ltd (CNTB) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CNTB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+15.65%

+8.28%

+2.82%

-1.92%

YTD

-9.57%

+18.60%

+171.28%

-89.15%

Financials & Valuation

TTM · Annual

Total Revenue	$64.00K
Net Income	$-55,480,000.00
Revenue Growth (YoY)	+5,666.67%
Gross Margin	100.00%
Operating Margin	-90,740.63%
Net Profit Margin	-86,687.50%
ROE	N/A
ROA · ROIC	-70.26% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2,452.52
P/B	3.79
P/FCF	N/A
EPS Growth	-5.88%
Outstanding Shares	62.97M

Technical Indicators

50-Day SMA	$2.21
200-Day SMA	$2.43
RSI (14)	75.00
Beta	-0.24
52-Week High	$3.74
52-Week Low	$1.24

Volume Today	54.59K
Avg Daily Volume (30D)	156.80K
Relative Volume	0.35x
Volatility (10D)	54.16
Volatility (30D)	83.70
Free Float	66.91%

Analyst Consensus

BUY

Current Price $2.55

Mean Target $7.25

52W Low$1.24 52W High$3.74

Current

Target

$1.24 $3.74

Current Analyst target

+184.31% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00ZGYNJZ5

ISINKYG235491019

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4R?) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4R?) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4R?, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.